knowledge -WSS

knowledge

author：knowledge 2025-09-09 05:35:40 - browse：59675

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： STAT Summit: How a Chicago ER doctor tackles gun violence

WSS

Food makers tried to stack nutrition panel with preferred experts

Pharmacists can make shortage drugs, but at what cost?

Popular nasal decongestant doesn't actually relieve congestion

FDA panel endorses Alnylam’s heart drug — after picking it apart

Impact of Dobbs ruling felt at reproductive medicine meeting

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Wikipedia

knowledge

focus

Hollywood unions extend contract negotiations for actors

NIH confirmation hearing shows politicization of research

Psychedelics group wrestles with new pharma identity

CEOs share strategies for surviving biotech slump

Bright Health sells Medicare Advantage business to Molina

Walmart eyes Medicare Advantage provider ChenMed

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT Summit: GSK CEO on pharma giant's new direction

In age of alternative facts, a scholarly course on calling out crap

Telehealth for opioid use disorder is lifesaving

focus

How climate

FDA proposes changes to key medical devices approval pathway

Diverse clinical trials: Why aren’t we there yet?

Telehealth for opioid use disorder is lifesaving

Impact of Dobbs ruling felt at reproductive medicine meeting

2023 STAT Wunderkinds: get to know the winners

entertainment

focus

hotspot

leisure time